Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan + Cisplatin in Recurrent Ovarian and Endometrial Cancer
NCT06040970Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2024
- Primary completion
- Jul 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in ovarian cancer, endometrial cancer (EC), sponsored by Icahn School of Medicine at Mount Sinai. Started Oct 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06040970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040970.